SCHEMBL3979519

SCHEMBL3979519

Cc1ccc(CS(=O)(=O)CC#N)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
POLB P06746 3/20 0.44
GLA P06280 1/20 0.43
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
LMNA P02545 1/20 0.40
ALDH1A1 P00352 3/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CYP2C19 P33261 2/20 0.38
MAPT P10636 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
S100A4 P26447 1/20 0.37
MTOR P42345 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4400952 0.81 KMT2A (0.62) KMT2APOLBLMNAALDH1A1CA1
SCHEMBL4071279 0.81 KMT2A (0.41) KMT2ALMNAALDH1A1MEN1CYP3A4
SCHEMBL1169955 0.80 CA1 (0.48) KMT2ALMNAALDH1A1CA1CA2
SCHEMBL10289671 0.77 KMT2A (0.58) KMT2APOLBLMNAALDH1A1CA1
SCHEMBL4250031 0.77 TSHR (0.47) KMT2APOLBALDH1A1CA1CA2
SCHEMBL1958962 0.77 KIF11 (0.51) KMT2ABCHEACHECA1CA2
SCHEMBL9820153 0.74 KMT2A (0.59) KMT2APOLBBCHEACHELMNA
SCHEMBL5745852 0.73 BCHE (0.42) KMT2ABCHEACHEALDH1A1CA1
SCHEMBL1169954 0.72 ALDH1A1 (0.55) KMT2AGLABCHEACHELMNA
SCHEMBL14426922 0.72 KMT2A (0.62) KMT2APOLBLMNAALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572113-B1 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2017-05-17 EP disclosed
EP-1572113-B1 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2017-05-17 EP disclosed
US-9447100-B2 Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) 2016-09-20 US disclosed
US-9447100-B2 Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) 2016-09-20 US disclosed
US-9447100-B2 Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) 2016-09-20 US disclosed
US-20140155416-A1 SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-06-05 US disclosed
US-20140155416-A1 SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-06-05 US disclosed
US-20140155416-A1 SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-06-05 US disclosed
US-20090215746-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) 2009-08-27 US disclosed
US-20090215746-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) 2009-08-27 US disclosed
US-20090215746-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) 2009-08-27 US disclosed
US-7514441-B2 Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-07 US disclosed
US-7514441-B2 Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-07 US disclosed
EP-1572113-A4 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-11-22 EP disclosed
US-20060079536-A1 Calcium receptor modulating compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-13 US disclosed
EP-1572113-A2 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-09-14 EP disclosed
WO-2004017908-A2 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215746-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS CASR, NR2C2, RYR1 KMT2A 3123/4885POLB 4328/4885GLA 3890/4885
US-20060079536-A1 Calcium receptor modulating compound and use thereof CASR, NR2C2, CALCR KMT2A 2825/4885POLB 4831/4885GLA 3570/4885
US-20140155416-A1 SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS CASR, NR2C2, RYR1 KMT2A 3123/4885POLB 4328/4885GLA 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.